Epigenetics: Tools, Diagnostics, Drugs and World Market
| Product Code | TKD00013 |
| Publication Date | August 2010 |
| Publisher | Takeda Pacific |
| Product Type | Report |
| Pages | 150 |
| ISBN Number | not applicable |
Epigenetics: Tools, Diagnostics, Drugs and World Market
This broad and high-level report examines the emerging epigenetics market. This world market includes important biomedical product areas that will have a powerful impact on healthcare delivery and personalized medicine. This business report analyzes key market segments such life science research tools, diagnostics and therapeutics.
Many people already know about DNA, genes and the human genome. The DNA code defines the structure of who we are, our potential health and our characteristics that we pass on to our children. Epigenetics refers to the second code of life and links environmental impacts to a person’s health. Epigenetic mechanisms signal how and when genes are activated or silenced.
This research study discusses the market for life science tools and technologies that support epigenetics R&D. The report discusses important technologies, equipment and consumables including microarray, next-generation sequencing, PCR and other platforms. Topics such as microRNA and human stem cells are lightly covered.
The report covers subjects including important epigenetic factors including DNA methylation, histone modifications and others. The study discusses epigenetic biomarkers, commercial diagnostics and therapeutics that will foster personalized medicine. The study highlights new epigenetic diagnostics. This research examines the current epigenetic therapeutics on the market and drugs in the clinical pipeline. The report highlights major government grant initiatives such as the NIH’s ‘Roadmap Epigenomics Program’ initiatives, the EU’s ‘Epigenetic Network of Excellence’ and others.
This study discusses important epigenetics topics and provides the reader with key findings. The data estimates that the worldwide epigenetics market value will reach multi-billions of dollars in 2010, with a strong double-digit growth rate. This report reviews the activities of 35 companies. The study uses 39 figures and tables to illustrate the findings. This study includes many valuable tables that help the reader scan the details of major trends, market segmentation, forecast, M&As, partnerships, grant funding, patents and so on.
This must-have report would benefit people with job titles including CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.
Contents
1. The Epigenetics Market Landscape
Epigenetics for R&D, Diagnostics & Therapeutics
Brief History
Understanding Epigenetic Mechanisms
Epigenetics, Key Diseases and Demographics
Tools & Technologies for Epigenetic R&D
Epigenetic Diagnostic Tests
Epigenetic-Based Therapeutics
Key Business Applications
Academic Research Applications
Diagnostic Applications
Therapeutic Applications
2. Major Alliances, M&As and IP
Major Alliances and M&As In Epigenetics
Definitions of Deal Types
Summary of Major Epigenetics Alliances and M&As
Alliance and M&A Data Tables
Patents, Business Development and Challenges
Highlights of Companies That Own IP Involving Epigenetic Techs.
Valuations of Epigenetic Technologies and Products
Business Development Challenges
Patent Challenges
3. Epigenetics Market Forecast
Epigenetics Product Market Size, 2008~2013
Epigenetic Market by Product Segments
Epigenetic R&D Tools and Technologies Segments
Epigenetic Diagnostics Segments
Epigenetic Therapeutics Segments
WW Epigenetic Market By Vendor Product Shares, 2008 & 2013
Market by Major Diseases
Cancer Segment
Neuro-psychological (CNS) Segment
Infectious Disease Segment
Respiratory Segment
Reproductive Disease Segment
The ‘Others’ Segment
Epigenetic Market by R&D Developer Segments
Academic/Gov. Basic Life Science R&D Sub-segments
Diagnostics Developer Segments
Pharma/ Biotech Rx/Tx Developer Segments
Epigenetics Market by WW Regions
North America
Europe
Japan/ Asia Pacific
ROW
4. Selected Companies Working in Epigenetics
454 Life Sciences (Roche)
Abcam plc
Active Motif, Inc.
Affymetrix, Inc.
Agilent Technologies, Inc., BAM/LS
Applied Biosystems Group
AVIVA Systems Biology
BioServe
Cogenics (Clinical Data)
DNASTAR, Inc.
Epigenomics AG
Epigentek, Inc.
Epiontis GmbH
Fluidigm Corporation
GATC Biotech AG
GeneGo, Inc.
Genomatix Software GmbH
GenomeQuest, Inc.
Genpathway, Inc.
Human Genetic Signatures Pty. Ltd.
Illumina, Inc.
Invitrogen
Methylgene, Inc.
MGI Pharma, Inc. (subsidiary of Eisai)
Millipore
OncoMethylome Sciences SA
Orion Genomics LLC
Qiagen N.V.
Regulus Therapeutics LLC
Roche Nimblegen
Rubicon Genomics, Inc.
Sequenom
SeqWright, Inc.
Sigma-Aldrich Co.
Zymo Research Corp.
5. Findings and Conclusions
Epigenetics Market Future Direction
Analytical Tools for Epigenetic R&D
Commercial DNA Microarrays, ChIP on Chip and Methylation
High-Throughput Sequencing and ChIP-Seq.
Other Front Runner Technologies
Consumables & Reagent Kits
Commercial Diagnostic/ Test Services
Therapeutics Involving Epigenetics
Epigenetics Market Drivers and Restraints
The US NIH Roadmap Epigenomics Program Initiatives
The European Union Epigenetics Initiative
M&A Deals Have Helped Epigenetic Product Companies
FDA Approved Epigenetic Diagnostics Have Reached the Market
FDA Approved Epigenetic Therapeutics Have Reached the Market
Potential Business Opportunities
Opportunities for American and European Companies
Epigenetic Diagnostics
Consider Other World Regions for Cost Savings or New Customers
Market into Asia for Business Opportunities
Business Opportunities for Asian Companies
6. Appendix
Epigenetics Glossary
Company Contacts
Selected Grant Recipients for Epigenetics or Epigenomic Projects
About Takeda Pacific
About the Authors
List of Tables
Table 1. Epigenetics Disease Demographics
Table 2. Summary of Major Alliances and M&As, 2005 to Oct.- 2008
Table 3. Alliances and M&As Jan. to Oct. 2008
Table 4. Major Alliances and M&As - 2007
Table 5. Major Alliances and M&As - 2006
Table 6. Major Alliances and M&As - 2005
Table 7. Epigenetics Related US Patents Issued to Orgs., 2007 to Oct.- 2008
Table 8. Valuations of Major M&As Involving Epigenetics.
Table 9. Total WW Epigenetic Product Market Revenues, 2008-2013
Table 10. WW Epigenetic Market By Vendor Products $M
Table 11. Epigenetic R&D Tools & Technologies Sub-segments $M
Table 12. Epigenetic Diagnostics Sub-segments $M
Table 13. Epigenetic Therapeutics Sub-segments $M
Table 14. WW Epigenetic Market By Vendor Product Shares, 2008 & 2013
Table 15. WW Epigenetic Market By Leading Diseases $M
Table 16. Major Cancer Types Targeted in R&D and Shares
Table 17. WW Epigenetic Market By Developer Segments $M
Table 18. Academic/Gov. Basic Life Science R&D $M
Table 19. Diagnostics Developers
Table 20. Pharma/ Biotech Rx/Tx Developers
Table 21. WW Epigenetic Market By Regions $M
Table 22. High-Density Whole Genome Microarrays for Epigenetics
Table 23. High-Throughput DNA Sequencing For Epigenetics
Table 24. Other Technologies for Epigenetics
Table 25. Epigenetic Diagnostics Development Pipeline
Table 26. Therapeutics in Clinical Pipeline Involving Epigenetics
Table 27. NIH Roadmap Epigenomics Program Initiatives
Table 28. Glossary of Epigenetic Terms
Table 29. List of Company Contacts
Table 30. Selected NIH Grant Recipients and Epigenomic Projects
List of Figures
Figure 1. The Epigenetic Market Ecosystem
Figure 2. Highlights of Epigenetic Mechanisms
Figure 3. Growing Number of PubMed Articles About Epigenetics
Figure 4. Total WW Epigenetic Product Market Revenues, 2008-2013
Figure 5. WW Epigenetic Market By Vendor Products $M
Figure 6. WW Epigenetic Market By Product Market Shares, 2008 & 2013
Figure 7. WW Epigenetic Market By Major Diseases $M
Figure 8. WW Epigenetic Market By Developer Segments $M
Figure 9. WW Epigenetic Market By Regions $M